Lecture Details - Overview

1. LECTURE OVERVIEW
2. TABLE OF CONTENTS
3. FACULTY
4. TECHNICAL HELP

Accreditation and Credit Designation

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 26.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

• Discuss breast carcinogenesis and the impact of germline mutations on patient management
• Discuss advances in breast cancer imaging and early detection, including mammography, ultrasound, MRI, and PET scanning
• Review the clinical utility and limitations of sentinel lymph node biopsy
• Integrate diagnostic, prognostic, and predictive factors that provide biologic information about breast cancer subtypes into patient management decisions
• Integrate current staging guidelines into clinical decision making regarding local and systemic therapies
• Assess optimal radiation therapy strategies for treatment of patients with DCIS and early-stage and locally advanced breast cancer
• Critically analyze the data guiding the choice of adjuvant therapies for patients with low- and high-risk breast cancer
• Explore current and emerging strategies for ameliorating or eliminating therapy-associated adverse events
• Assess the evidence supporting an emphasis on quality of life and rehabilitation during and after breast cancer treatment
• Evaluate the evidence-based treatment recommendations for the management of patients with hormone-dependent and hormone-independent metastatic breast cancer
• Evaluate organ-specific therapeutic interventions for patients with metastatic disease to the CNS or skeleton
• Integrate palliative care strategies into treatment algorithms for metastatic disease

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians' Education Resource requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians' Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from School of Breast Oncology have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

Lauren Abrey, MD
Paid Consultant/Advisory Board – Celgene Corporation (spouse); Genentech, Inc.; Novartis Pharmaceuticals Corporation
Research Funding – Eli Lilly and Company; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Schering-Plough Corporation

D. Craig Allred, MD
No relevant financial relationships to disclose

Douglas Arthur, MD
Paid Consultant – SenoRx

Harold Burstein, MD, PhD
No relevant financial relationships to disclose

Lisa Carey, MD
Speaker's Bureau – Genentech, Inc.; GlaxoSmithKline
Research Funding – Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline

Rowan Chlebowski, MD, PhD
Paid Consultant/Advisory Board – AstraZeneca, Elli Lilly and Company, Novartis Pharmaceuticals Corporation, Organon USA, sanofi-aventis
Speaker's Bureau – AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation
Research Funding – Elli Lilly and Company; Organon International

Peter Eby, MD
Research Funding – Ethicon Endo-Surgery, General Electric Company

David Euhus, MD, FACS
No relevant financial relationships to disclose

Carol Fabian, MD
Paid Consultant/Advisory Board – Pfizer Inc.
Research Funding – Eisai Medical Research Inc.; Genentech, Inc.; GlaxoSmithKline; InterGenetics Incorporated; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Other Remuneration – AstraZeneca

William J. Gradishar, MD
Paid Consultant/Advisory Board – AstraZeneca, Novartis Pharmaceuticals Corporation, Pfizer Inc.
Speaker's Bureau – AstraZeneca, Novartis Pharmaceuticals Corporation, Pfizer Inc.

Julie Gralow, MD
Paid Consultant/Advisory Board – Eisai Medical Research Inc., Novartis Pharmaceuticals Corpor-ation, Roche Pharmaceuticals
Research Funding – Amgen; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Roche Pharmaceuticals; sanofi-aventis

Karin Hahn, MD, MPH, MSc
No relevant financial relationships to disclose

Eleanor Harris, MD
No relevant financial relationships to disclose

Syed Hoda, MD
No relevant financial relationships to disclose

Frankie Anne Holmes, MD, FACP
Paid Consultant/Advisory Board – Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals
Speaker's Bureau – Novartis Pharmaceuticals Corporation

Claudine Isaacs, MD
Speaker's Bureau – Genentech, Inc.; Genomic Health, Inc.

Steven Kronowitz, MD, FACS
No relevant financial relationships to disclose

Henry Kuerer, MD, PhD, FACS
Paid Consultant/Advisory Board – Genentech, Inc.
Research Funding – Genentech, Inc.

Charles Loprinzi, MD
Paid Consultant/Advisory Board – Astellas Pharma US, Inc.; Tsumonas

Eleftherios Mamounas, MD
Paid Consultant/Advisory Board – Abraxis Oncology; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche Pharmaceuticals; sanofi-aventis
Speaker's Bureau – Genentech, Inc.; Genomic Health, Inc.; Novartis Pharmaceuticals Corporation; sanofi-aventis

Matthew Mayo, PhD, MBA
No relevant financial relationships to disclose

Anne McTiernan, MD, PhD
Paid Consultant/Advisory Board (spouse) – Merck & Co., Inc.; Rosetta Inpharmatics
Stock/Investment Holder (spouse) – Merck & Co., Inc.

Anne Moore, MD
No relevant financial relationships to disclose

Ruth O'Regan, MD
Speaker's Bureau – AstraZeneca; Genentech, Inc.; Genomic Health, Inc.; Novartis Pharmaceuticals Corporation
Research Funding – sanofi-aventis

Joyce O'Shaughnessy, MD
Paid Consultant/Advisory Board – AstraZeneca; Eisai Medical Research Inc.; Genentech, Inc.; Molecular Profiling, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; sanofi-aventis
Speaker's Bureau – Abraxis Oncology, AstraZeneca, Eli Lilly and Company, sanofi-aventis

Beth Overmoyer, MD, FACP
Paid Consultant/Advisory Board – GlaxoSmithKline, sanofi-aventis

Soon Myung Paik, MD
Paid Consultant/Advisory Board – Genentech, Inc.; GlaxoSmithKline

Edith Perez, MD
Research Funding – Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; Pfizer Inc.; sanofi-aventis

Lori Pierce, MD
No relevant financial relationships to disclose

Elizabeth Rafferty, MD
Research Funding – Hologic, Inc.

Peter Ravdin, MD, PhD
Board of Directors/Other Leadership Role – Adjuvant Inc.
Paid Consultant/Advisory – Board Genomic Health, Inc.
Research Funding – AstraZeneca
Other Remuneration – Adjuvant, Inc.

Hope Rugo, MD
Speaker's Bureau – AstraZeneca; Genomic Health, Inc.
Research Funding – Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche Pharmaceuticals; sanofi-aventis

Charles Shapiro, MD
Paid Consultant/Advisory Board – AstraZeneca; Genentech, Inc.; Pfizer, Inc.
Speaker's Bureau – Pfizer Inc.
Research Funding – Genentech, Inc.; Pfizer Inc.; sanofi-aventis

Thomas Smith, MD
Paid Consultant/Advisory Board – Medtronic, Inc.
Speaker's Bureau – Medtronic, Inc.
Research Funding – National Library of Medicine

Edward Staab, MD
No relevant financial relationships to disclose

Anthony Tolcher, MD
Paid Consultant/Advisory Board – Amgen; Anadys Pharmaceuticals, Inc.; ARIAD Pharmaceuticals, Inc.; AstraZeneca, Astellas Pharma Inc.; Biogen Idec; Centocor, Inc.; Compound Therapeutics, Inc.; Cytokinetics, Inc.; Daiichi Sankyo, Inc.; Eli Lilly and Company; Exelixis, Inc.; FibroGen, Inc.; Five Prime Therapeutics; Genentech, Inc.; Genetics Squared, Inc.; Genta Incorporated; HUYA Bioscience International; ImmunoGen, Inc.; Johnson & Johnson; MGI PHARMA; Micromet, Inc.; Nereus Pharmaceuticals; Paramount BioSciences, LLC; Park Place Pharmaceuticals; Pfizer Inc.; sanofi-aventis; Schering-Plough Corporation; SuperGen

Jeffrey Weitzel, MD
No relevant financial relationships to disclose

Eric Winer, MD
Research Funding – Genentech, Inc.; GlaxoSmithKline

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

• Microsoft Internet Explorer Downloads (Outside Source)
• Mozilla Firefox Product Page (Outside Source)
• Adobe Flash Player 9 (Outside Source)

Macintosh Users
Compatible Web browsers include

• Firefox (Outside Source)
• Apple Safari (Outside Source).
• Adobe Flash Player 9 (Outside Source)

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the faculty and Physicians' Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy

Physicians' Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2008 by Physicians' Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, School of Breast Oncology
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3456
Fax: (214) 367-3304
E-mail: editor@pergrouplp.com

Educational Grants

An educational grant for this activity was provided by:

1. Novartis Oncology
2. Eisai, Inc.
3. AstraZeneca
4. Abraxis BioScience
5. GlaxoSmithKline
6. Genentech BioOncology
7. Pfizer Oncology
8. Bristol-Myers Squibb